Amyloid Beta Recombinant Proteins

Amyloid Recombinant Proteins 

Amyloid beta (Aβ) recombinant proteins are critical tools for studying the pathology of Alzheimer’s disease (AD) and other neurodegenerative disorders. Aβ is a peptide derived from the amyloid precursor protein (APP) through sequential cleavage by β- and γ-secretases. These peptides, particularly Aβ40 and Aβ42, can aggregate into oligomers and fibrils, forming plaques in the brain—a hallmark of AD. 

Content

• Structure and Variants:
  • Aβ peptides are 39–43 amino acids long, with Aβ40 and Aβ42 being the most studied.
  • Aβ42 is more prone to aggregation and is closely associated with neurotoxicity and plaque formation.
  • Recombinant Aβ proteins can be produced as monomers, oligomers, or fibrils for specific applications.
• Expression Systems:
  • Bacterial Systems (e.g., E. coli): Commonly used for high-yield production of Aβ.
  • Synthetic Peptide Synthesis: Ensures high purity and sequence fidelity.
  • Cell-Free Systems: Allow rapid production and isotopic labeling for NMR studies.

Applications

• Alzheimer’s Disease Research:
  • Investigating Aβ aggregation pathways and plaque formation.
  • Studying the neurotoxic effects of Aβ oligomers and fibrils on neurons.
  • Exploring the role of Aβ in synaptic dysfunction and neuronal death.
• Drug Discovery and Screening:
  • High-throughput screening of small molecules or antibodies targeting Aβ aggregation.
  • Evaluating the efficacy of therapeutic agents designed to inhibit or reverse Aβ fibril formation.
  • Testing compounds for reducing Aβ production through secretase modulation.
• Immunological Research:
  • Developing antibodies targeting Aβ for immunotherapy.
  • Investigating immune responses to Aβ plaques in neuroinflammation.

Amyloid beta recombinant proteins are indispensable for advancing our understanding of Alzheimer’s disease and developing diagnostic and therapeutic strategies to combat neurodegeneration.